Biotin may interfere with certain laboratory tests
Non-Incretin Pathways: Novel Mechanisms of Action Research is exploring pathways independent of the traditional incretin system to address limitations like side effects and weight plateaus
This partial reversal may be driven by factors such as compliance challenges, waning drug efficacy, or measurement limitations
It does not prove all four identities, the amount of each peptide, copper coordination, ratio accuracy, vial-to-vial uniformity, sterility, endotoxin control, aggregation or stability
In July 2025, CVS Caremark made a significant formulary change that affected millions of Aetna members: tirzepatide (Zepbound) was removed from the standard national formulary for obesity